Background. The biological diagnosis of toxoplasmosis after allogeneic hematopoietic stem cell transplantation (HSCT) is based on the detection of Toxoplasma gondii DNA in blood specimens or other samples. Serological testing is used mainly to defin the immunity status of the patient before HSCT. The aim of our study was to examine the performance of polymerase chain reaction (PCR) and serological techniques in the diagnosis of toxoplasmosis after HSCT.
Toxoplasmosis after allogeneic hematopoietic stem cell transplantation (HSCT) remains a cause of severe infection and is associated with a high mortality rate [1] . Various studies have estimated a toxoplasmosis risk of 0.3%-5.0% after allogeneic HSCT, depending on the prevalence of Toxoplasma gondii in the population [2] [3] [4] [5] , but the true incidence of toxoplasmosis among immunocompromised patients is difficul to assess, be-cause in many instances, the diagnosis is overlooked [6] . Recent single-center and multicenter retrospective studies [7] have suggested that invasive disease may be more common than was previously known, with incidences among T. gondii-seropositive recipients of allogeneic transplants of up to 4% and an estimated mortality rate of 60%-90%. The major site of infection is the brain, with a focal mass presentation or, less commonly, diffuse encephalitis [3, 8] . Myocarditis, pneumonitis [9] , hepatitis, chorioretinitis, and disseminated disease may also complicate the course of toxoplasmosis in immunocompromised hosts [1, 4] . The clinical presentation is nonspecific and the pleiomorphic manifestation of toxoplasmosis makes it difficul to obtain a definit antemortem diagnosis [10] . Studies underscore the need for rapid diagnostic tests in an effort to improve the outcome [2] . Serological testing is used mainly to identify at-risk patients prior to allogeneic HSCT [10] . PCR has been shown to be sensitive in immunocompromised patients with disseminated toxoplasmosis [11] [12] [13] [14] and may represent a better modality for early identificatio of infection [10] . Routine PCR testing of peripheral blood specimens may be an appropriate tool to guide preemptive therapy for patients at very high risk of developing invasive disease [7, 15, 16] . The aim of this study was to retrospectively analyze the combined results of PCR and serological techniques in a survey of 70 allogeneic HSCT recipients and to determine the prevalence of invasive toxoplasmosis.
PATIENTS AND METHODS

Patients.
Seventy consecutive adult patients received HSCTs from September 2004 through September 2006 in the Hematologic Department of Grenoble University Hospital (Grenoble, France). Serological testing was performed on baseline pretransplantation samples obtained from each patient. After transplantation, the patients were systematically monitored by PCR performed on blood samples obtained every 2 weeks during immunosuppressive treatment and were monitored less systematically by serological testing. If toxoplasmosis was suspected, PCR was performed more frequently (every 2 days) on blood samples and/or on another sample from the involved organ (usually CSF or bronchoalveolar lavage fluid) After engraftment, primary prophylaxis with trimethoprim-sulfamethoxazole was recommended for all patients when possible (∼1 month after HSCT). Yet, if intolerance or persistent neutropenia occurred, alternative prophylaxis decisions were made. If a patient was found to have PCR results positive for T. gondii without clinical symptoms, no treatment was initiated. If a patient developed Toxoplasma disease, therapy including pyrimethamine-sulfadiazine or pyrimethamine-clindamycin was initiated on the basis of biological, clinical, and radiological evidence.
Methods. The parasite DNA was detected using a qualitative PCR system, described elsewhere [17] , that was designed to use the B1 target gene and that uses an internal control to monitor inhibition, as well as an amplicon carry-over contamination control with a sensitivity level of 1 parasite. Anti-T. gondii IgM was detected by ELISA (Vidas; bioMérieux), indirect immunofluo escence, and immunosorbent agglutination assay (bioMérieux) [18] . Anti-T. gondii IgG was detected by ELISA (Vidas; bioMérieux) and indirect immunof uorescence [19] . Definitions T. gondii infection and disease were define according to the European Group for Blood and Marrow Transplantation-Infectious Diseases Working Party Guidelines [7] . In brief, T. gondii infection was define as being present in a patient who had positive results of PCR performed on blood samples and no evidence of organ involvement, with or without fever. Definit toxoplasmosis was define as histological evidence of active Toxoplasma disease found in a clinically and radiologically involved organ, whereas probable toxoplasmosis was define as positive results of PCR performed on a blood sample and/or another sample from the involved organ (usually CSF or bronchoalveolar lavage fluid with clinical signs and symptoms and radiological evidence of active disease.
RESULTS
Biological test results.
Before HSCT, serological testing was performed to determine the immune status of the recipients. The results of specifi IgG detection testing were positive for 40 (57.1%) of 70 HSCT recipients. The results of specifi IgM detection testing were negative for 69 (98.6%) of 70 HSCT recipients; the 1 HSCT recipient with positive results had residual IgM detected. After HSCT, 4 recipients (5.7%) who had Toxoplasma disease had at least 4 samples with positive biological test results (i.e., presence of T. gondii DNA or IgM or both) (table 1). The 57 patients (81.4%) with negative IgM test results and negative DNA detection results had no T. gondii infection. The 9 other patients (12.8%), who had 1 or 2 samples with positive PCR results and negative IgM results, were con-sidered to have T. gondii infection without disease; these patients experienced a favorable outcome without any specif c antitoxoplasmic treatment. The predictive value of having 1 sample with a positive PCR result was 25%. Thus, the incidence of Toxoplasma disease was 5.7%, and the incidence of T. gondii infection was 12.8%.
Characteristics and outcome of Toxoplasma disease. Characteristics and outcomes of the 4 recipients with toxoplasmosis are shown in table 2. These 4 recipients received suppressive treatment, but 3 recipients (patients 1, 2, and 3) received transplants from unrelated donors and developed graft-versus-host disease of grade I or II. None of the patients had received anti-T. gondii prophylaxis. Two recipients (patients 1 and 2) developed cerebral toxoplasmosis, and the other 2 recipients (patients 3 and 4) developed disseminated toxoplasmosis with respiratory distress. The disease onset was earlier for the 2 recipients with pulmonary symptoms (patient 3, onset at day 27; patient 4, onset at day 33) than for the 2 recipients with neurological symptoms (patient 1, onset at day 114; patient 2, onset at day 153). Before the allograft was performed, 3 recipients (patients 2, 3, and 4) had serological test results that were positive for T. gondii IgG. In patients 2, 3, and 4, toxoplasmosis seemed to occur through reactivation of latent cysts into invasive tachyzoites. In patient 1, the recipient and the donor were seronegative, the results of PCR performed on 10 blood samples and 1 CSF sample were negative, and toxoplasmosis occurred as a primary infection with a typical seroconversion (figu e 1A). The symptoms included abnormal movements of all 4 limbs and of the eyes. Treatment with pyrimethamine-clindamycine was effective. Patient 2 had fever and somnolence. Two peripheral blood samples yielded positive PCR results on days 165 and 168 after transplantation (figu e 1B) and confi med the presence of toxoplasmosis. The results of a PCR performed on 1 CSF sample were negative. Subsequently, 2 relapses of toxoplasmosis were observed after stopping antiparasitic treatment. The results of biological testing performed after the firs relapse were negative, and the diagnosis was confi med by a cerebral CT. A second relapse occurred on day 800, and biological test results revealed an increased IgM level, but PCR results were negative. Patient 3, who had pulmonary toxoplasmosis, received a toxoplasmosis diagnosis on the basis of positive results of PCR performed on bronchoalveolar lavage fluid but the patient died before treatment could be administered (figu e 1C). A retrospective analysis of the serum samples obtained 27, 34, 43, and 49 days before this patient's death revealed the presence of IgM. Patient 4 received a diagnosis on the basis of positive results of PCR performed on bronchoalveolar lavage flui on day 36 after transplantation (figu e 1D). Giemsa fast staining and microscopic observation of the bronchoalveolar lavage flui sample obtained on day 46 revealed tachyzoites of T. gondii. In this case, tests to detect IgM had negative results. Treatment with pyrimethamine-clindamycin was started, but the patient died on day 59.
Characteristics and outcome of T. gondii infection. Table 3 shows the demographic and clinical characteristics and outcomes for the 9 patients with 1 or 2 blood samples with positive PCR results. Before the allograft was received, 6 of 9 recipients had serological tests with results that were positive for T. gondii (i.e., positive for IgG). In 6 patients, the serostatus of the donor was positive, and 3 patients (patients 10, 11, and 12) received transplants from unrelated donors. Seven patients (patients 5, 6, 7, 9, 10, 12, and 13) received suppressive treatment, and 4 patients (patients 5, 9, 10, and 12) developed graftversus-host disease of grade I or II. Only 1 of 9 patients received anti-T. gondii prophylaxis. No signs of toxoplasmosis were observed. The 9 patients did not receive treatment with anti-T. gondii drugs, and the outcomes were favorable for all patients.
DISCUSSION
Few studies [1, 3, 20] have analyzed the incidence of T. gondii infection and disease in patients after allogeneic HSCT. Martino et al. [7] described the results of a prospective study of the incidence of reactivation of toxoplasmosis that was performed at 5 European transplantation centers and involved 106 T. gondii-seropositive adult recipients of HSCT. They found an incidence of 16% for T. gondii infection and 6% for Toxoplasma disease. In our study, the incidence of T. gondii infection was 12.8%, and the incidence of Toxoplasma disease was 5.7%. However, the patients in our study had positive or negative serological test results obtained before HSCT. The seropositive patients were at risk for reactivation of latent cysts, whereas the seronegative patients were at risk for primary T. gondii infection. Thus, toxoplasmosis is more common after HSCT than has been previously suggested [2] [3] [4] [5] . The incidence of toxoplasmosis in our study approximated that in the study by Martino et al. [7] .
Toxoplasmosis after HSCT is a severe infection that is associated with a high mortality rate [1, 10, 21] . Analysis of our data also indicates that infections that occur late after transplantation (e.g., patients 1 and 2; table 2) may have a better prognosis than infections that occur soon after transplantation (e.g., patients 3 and 4). The low rate of late reactivation is probably attributable to the fact that immune recovery improves with time after HSCT [1] . The patients who received HSCTs from unrelated donors (3 of the 4 recipients in our study) possibly had a higher risk of toxoplasmosis than did patients who received HSCTs from related donors. PCR techniques to detect the presence of T. gondii DNA in peripheral blood and other samples may help to establish the toxoplasmosis diagnosis [14, 22] . The PCR used in this work was qualitative. However, this is not a major drawback, because no clear threshold level for therapy has been described to date. Our Table 2 . Clinical characteristics of patients with toxoplasmosis. study shows that the detection of IgM may be important for obtaining a diagnosis of toxoplasmosis in some patients. For 2 patients, the detection of specifi anti-T. gondii IgM was the only biological evidence of toxoplasmosis (patient 1) or relapse (patient 2). For 1 patient (patient 3), IgM was detected before positive PCR results were obtained. For the biological followup of patients undergoing allogeneic HSCT, no consensus exists on the optimal protocol to be used in clinical laboratories. We recommend monitoring by PCR of blood samples and serological testing once every 2 weeks during immunosuppressive therapy after transplantation. Reactivation of latent tissue cysts in previously infected individuals is the usual mechanism involved in toxoplasmosis that occurs after HSCT [1] . Therefore, it is important to determine the patient's serostatus before transplantation and to monitor the patient with negative specifi serological tests to detect potential new infection. Three patients with toxoplasmosis infection were seronegative before transplantation but had test results that were positive for IgG after HSCT. A negative test result obtained before allograft does not always mean the absence of T. gondii immunity, because deep immunosuppression may reduce the level of anti-T. gondii antibodies. Therefore, all of the patients with test results negative for IgG before allograft, as well as those with test results positive for IgG, should be followed up with PCR and serological testing. The need for T. gondii prophylaxis before HSCT in transplant recipients should be better defined and T. gondii prophylaxis should preferably be combined with Pneumocystis jiroveci prophylaxis [6] . For prophylaxis, we propose the use of cotrimoxazole or pyrimethamine combined with pentamidin.
In conclusion, toxoplasmosis is a serious health problem among HSCT recipients that can lead to death. Reactivation of latent infection is the most common cause of toxoplasmosis in such patients. However, toxoplasmosis can also occur as a primary infection. After allogeneic HSCT, all patients are at risk of toxoplasmosis and should be followed up with biological testing. We recommend the use of PCR performed on blood samples and serological testing to detect anti-T. gondii IgM and IgG.
